Modality
Gene Editing
MOA
IL-13i
Target
CD3
Pathway
Hedgehog
RAMDS
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
Jul 2019
→ May 2030
Phase 2Current
NCT07152833
2,123 pts·MDS
2022-05→2030-05·Recruiting
NCT06026815
2,197 pts·MDS
2019-07→2028-03·Recruiting
4,320 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-03-212.0y awayPh2 Data· MDS
2030-05-204.1y awayPh2 Data· MDS
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2028-03-21 · 2.0y away
MDS
Ph2 Data
2030-05-20 · 4.1y away
MDS
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07152833 | Phase 2 | MDS | Recruiting | 2123 | HbA1c |
| NCT06026815 | Phase 2 | MDS | Recruiting | 2197 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Miriglumide | Alnylam | Phase 3 | CD3 |